DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hewitt, N. J.
Right arrow Articles by Utesch, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hewitt, N. J.
Right arrow Articles by Utesch, D.

Vol. 29, Issue 7, 1042-1050, July 2001

SHORT COMMUNICATION
Studies Comparing in Vivo:in Vitro Metabolism of Three Pharmaceutical Compounds in Rat, Dog, Monkey, and Human Using Cryopreserved Hepatocytes, Microsomes, and Collagen Gel Immobilized Hepatocyte Cultures

Nicola J. Hewitt, Karl-Uhlrich Bühring, Johannes Dasenbrock, Jutta Haunschild, Bernhard Ladstetter, and Dietmar Utesch

Institute of Toxicology, Merck KGaA, Darmstadt, Germany (N.J.H., D.U.); and Institute of Pharmacokinetics and Metabolism, Merck KGaA, Grafing, Germany (K.-U.B., J.D., J.H., B.L.)

The in vivo metabolism of three pharmaceutical compounds, EMD68843, EMD96785, and EMD128130, was compared in fresh and cryopreserved hepatocyte (CPH) suspensions and microsomes from rat, dog, monkey, and human livers and fresh human and rat hepatocyte collagen gel immobilized cultures (GICs). Half of the major in vivo metabolites was produced by phase 1 (hydroxylation, oxidation, hydrolysis, N-dealkylation) and half by phase 2 metabolism (mostly glucuronidation but also sulfation and glycine conjugation). The identity and percentage of phase 1 and 2 metabolites from each compound produced in hepatocytes compared well with that in each species in vivo. Glucuronidation was more extensive in GICs than in CPHs. In contrast, CPHs but not GICs, produced sulfate metabolites. Microsomes (supplemented with NADPH only) produced most of the phase 1 but no phase 2 metabolites. Metabolism in CPHs was the same as in fresh hepatocyte suspensions. Discrete species differences in metabolism were detected by CPHs and microsomes. Cytochrome P450 and glucuronosyl S-transferase contents of CPHs did not account for species differences in the percentage of phase 1 and 2 metabolites or the rate of disappearance of the parent compounds in these cells. These data show a good correlation between major metabolites formed in vivo and in vitro. CPHs and GICs, unlike microsomes, carried out sequential phase 1 and 2 metabolism. Each in vitro system has its own advantages, however, for short-term metabolism studies CPHs may be more useful since they are readily available, easier and quicker to prepare than GICs, and have more comprehensive enzyme systems than microsomes.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
L. J. Christopher, D. Cui, W. Li, A. Barros Jr., V. K. Arora, H. Zhang, L. Wang, D. Zhang, J. A. Manning, K. He, et al.
Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys
Drug Metab. Dispos., July 1, 2008; 36(7): 1341 - 1356.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
T. S. Poet, H. Wu, J. C. English, and R. A. Corley
Metabolic Rate Constants for Hydroquinone in F344 Rat and Human Liver Isolated Hepatocytes: Application to a PBPK Model
Toxicol. Sci., November 1, 2004; 82(1): 9 - 25.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. F. McGinnity, M. G. Soars, R. A. Urbanowicz, and R. J. Riley
EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE
Drug Metab. Dispos., November 1, 2004; 32(11): 1247 - 1253.
[Abstract] [Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
N. J Hewitt and D. Utesch
Cryopreserved rat, dog and monkey hepatocytes: measurement of drug metabolizing enzymes in suspensions and cultures
Human and Experimental Toxicology, June 1, 2004; 23(6): 307 - 316.
[Abstract] [PDF]


Home page
Drug Metab. Dispos.Home page
Y. Naritomi, S. Terashita, A. Kagayama, and Y. Sugiyama
Utility of Hepatocytes in Predicting Drug Metabolism: Comparison of Hepatic Intrinsic Clearance in Rats and Humans in Vivo and in Vitro
Drug Metab. Dispos., May 1, 2003; 31(5): 580 - 588.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. A. Graham, A. Downey, D. Mudra, L. Krueger, K. Carroll, C. Chengelis, A. Madan, and A. Parkinson
In Vivo and in Vitro Induction of Cytochrome P450 Enzymes in Beagle Dogs
Drug Metab. Dispos., November 1, 2002; 30(11): 1206 - 1213.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.